Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) today announced that it has granted stock options on January 25, 2019 to certain directors and employees of the Company. The stock options have an exercise price of $0.085 per...
Read More
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) is pleased to announce the closing of its private placement previously announced on January 11, 2019 of 3,558,573...
Read More
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) is pleased to announced the closing of its previously announced private placement of 11,532,000 common shares of the Company...
Read More
Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) announced that Echelon Wealth Partners, Inc. (“Echelon”) has initiated research coverage on Kalytera with a speculative "Buy" rating and a one-year price target of $0.30 per share. The Company is...
Read More
Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) today announced that the Company has elected to issue 9,387,831 common shares of the Company ("Common Shares") to The Salzman Group in payment of invoices issued under the payments agreement...
Read More
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) announced today that it is proceeding with a private placement under which it intends to sell up to...
Read More
No Patients Have Developed Grades 3-4 Acute GVHD While Receiving CBD Treatment Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive interim data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”)...
Read More
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) (OTCQB:KALTF) announced today that it has entered into agreements to sell an aggregate of 11,532,000 common shares of the...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the third quarter of 2018. (All dollars U.S. unless otherwise noted.) The Company recorded net income of approximately $1.8 million ($0.01 per...
Read More
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 3,963,988 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under...
Read More